Effects of nicotinamide, an inhibitor of PARS activity, on gut and liver O2 exchange and energy metabolism during hyperdynamic porcine endotoxemia

Intensive Care Med. 2001 Mar;27(3):586-92. doi: 10.1007/s001340000842.

Abstract

Objective: To investigate the effects of nicotinamide (NIC), an inhibitor of poly(ADP-ribose) synthetase (PARS), on intestinal and liver perfusion, O2 kinetics, and energy metabolism over 24 h of hyperdynamic porcine endotoxemia.

Design: Prospective, randomized, controlled experimental study with repeated measures.

Setting: Animal laboratory in a university hospital.

Subjects: Sixteen pigs, divided into two groups: nine endotoxemic animals without therapy (CON); seven animals treated with NIC.

Interventions: Pigs were anesthetized, mechanically ventilated, and instrumented. Intravenous E. Coli LPS was continuously infused over 24 h concomitant with fluid resuscitation. After 12 h of endotoxemia continuous i.v. infusion of NIC (10 mg/kg per hour) was administered until the end of the experiment.

Measurements and results: All animals developed hyperdynamic circulation with sustained increase in cardiac output and progressive fall in mean arterial pressure. NIC maintained blood pressure without affecting CO. Hepato-splanchnic macrocirculation was not modified by the treatment. Nevertheless, although NIC attenuated the progressive rise of ileal mucosal-arterial PCO2 gap, it failed to improve portal venous L/P ratio, a marker of the overall energy state of the portal venous drained viscera. Similarly, neither the increased hepatic venous L/P ratio nor the simultaneous drop in hepatic lactate uptake were influenced by NIC.

Conclusions: Although NIC maintained hemodynamic stabilization during long-term endotoxemia, it was unable to improve LPS-induced deterioration of the hepato-splanchnic energy metabolism. More potent and selective PARS inhibitors are needed to elucidate the role of a PARS-dependent pathway in a clinically relevant models of sepsis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Gas Analysis
  • Blood Pressure / drug effects
  • Cardiac Output / drug effects
  • Disease Models, Animal*
  • Drug Evaluation, Preclinical
  • Endotoxemia / drug therapy*
  • Endotoxemia / metabolism*
  • Endotoxemia / physiopathology
  • Energy Metabolism / drug effects*
  • Female
  • Hemodynamics / drug effects
  • Intestinal Mucosa / metabolism*
  • Intestines / drug effects*
  • Lactic Acid / blood
  • Liver / drug effects*
  • Liver / metabolism*
  • Male
  • Niacinamide / pharmacology
  • Niacinamide / therapeutic use*
  • Oxygen Consumption / drug effects*
  • Poly(ADP-ribose) Polymerase Inhibitors*
  • Prospective Studies
  • Random Allocation
  • Splanchnic Circulation / drug effects
  • Swine
  • Time Factors

Substances

  • Poly(ADP-ribose) Polymerase Inhibitors
  • Niacinamide
  • Lactic Acid